Previous 10 | Next 10 |
Shares of Pulmatrix Inc. (NASDAQ:PULM) traded at a new 52-week low today of $0.92. So far today approximately 2.6 million shares have been exchanged, as compared to an average 30-day volume of 1.8 million shares. Over the past year, Pulmatrix Inc. has traded in a range of $0.92 to $3.04 ...
Shares of Pulmatrix Inc. (NASDAQ:PULM) traded at a new 52-week low today of $0.92. So far today approximately 2.6 million shares have been exchanged, as compared to an average 30-day volume of 1.8 million shares. Pulmatrix Inc. (NASDAQ:PULM) has potential upside of 46.1% based on a curre...
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine PR Newswire LEXINGTON, Mass. , April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company develop...
Shares of Pulmatrix Inc. (NASDAQ:PULM) traded today at $0.91, breaking its 52-week low. Approximately 2.6 million shares have changed hands today, as compared to an average 30-day volume of 1.8 million shares. Over the past year, Pulmatrix Inc. has traded in a range of $0.91 to $3.04 and...
Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio Termination of License, Development and Commercialization Agreement with the Lung Cancer Initiative at Johnson & Johnson will Return Portfolio to Pulmatrix Pulmatrix to c...
Shares of Pulmatrix (PULM) are down 15.5% in afternoon trading after the company announced that Johnson & Johnson (JNJ) was terminating a licensing agreement for PUR1800, its candidate for acute exacerbations in chronic obstructive pulmonary disease (AECOP).Pulmatrix will also r...
Gainers: Evelo Biosciences (EVLO) +26%, Ikena Oncology (IKNA) 21%, Taysha Gene Therapies (TSHA) +19%, 180 Life Sciences (ATNF) +16%, Tiziana Life Sciences (TLSA) +14%.Losers: iRhythm Technologies (IRTC) -38%, Biophytis (BPTS) -25%, Greenw...
Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio Termination of License, Development and Commercialization Agreement with the Lung Cancer Initiative at Johnson & Johnson will Return Portfolio to Pulmatrix Pulmatrix to continue dev...
Pulmatrix (PULM): FY GAAP EPS of -$0.67 beats by $0.15.Revenue of $12.6M (+59.3% Y/Y) beats by $1.97M.Shares -1.35%.Press Release For further details see: Pulmatrix EPS beats by $0.15, beats on revenue
Pulmatrix Reports 2020 Financial Results and Provides Business Update Initiated PUR1800 Phase 1b study with data anticipated in Q4 2021 Pulmazole Ph2b study start anticipated Q1 2022 PUR3100 development candidate declared for pulmonary delivered DHE (dihydroergotamine) a...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...